IPR Limbo During the Arthrex Decisions
Tysabri® (natalizumab) Litigation Begins
Raising a New Rationale or Elaborating on a Previously Raised Issue?
Appealing IPR Decisions – Art. III Standing in the Context of Litigation Settlements and Licenses
Suspending the Rules: A Year’s Worth of USPTO Petitions
Improvements to Determinations of Haplotype Phase Patent Ineligible Under § 101
Bayer v. Baxalta: Federal Circuit Upholds Jury’s 17.78% Royalty Award for Patent Infringement by Adynovate® (Factor VIII, PEGylated)
Issue Preclusion Precluded PTAB’s Contrary Result in a Later Inter Partes Reexam
